Menu
Back to Journals » OncoTargets and Therapy » Volume 12
RETRACTED ARTICLE: MACC1 promotes angiogenesis in cholangiocarcinoma by upregulating VEGFA
Authors Peng T, Li Z, Li D, Wang S
Received 6 December 2018
Accepted for publication 9 February 2019
Published 8 March 2019 Volume 2019:12 Pages 1893—1903
DOI https://doi.org/10.2147/OTT.S197319
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Takuya Aoki
This paper has been retracted.
Peng T, Li Z, Li D, Wang S. Onco Targets Ther. 2019;12:1893-1903.
We, the Editor and Publisher of OncoTargets and Therapy are retracting the published article. The authors requested to correct the western blot images in Figure 1 after finding the images used for Figure 1E, MACC1 P6 and P7, had been duplicated. The journal agreed the images had been duplicated in error during the publication process. However, our follow up queries found the authors were unable to provide sufficient supporting information to validate the reported findings. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The authors listed in this publication have been informed.
We have been informed in our decision-making by our editorial policies and the COPE guidelines.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
© 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.